JP2009519212A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009519212A5 JP2009519212A5 JP2008537892A JP2008537892A JP2009519212A5 JP 2009519212 A5 JP2009519212 A5 JP 2009519212A5 JP 2008537892 A JP2008537892 A JP 2008537892A JP 2008537892 A JP2008537892 A JP 2008537892A JP 2009519212 A5 JP2009519212 A5 JP 2009519212A5
- Authority
- JP
- Japan
- Prior art keywords
- xaa
- ome
- hsdavfteqy
- seq
- peg20k
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940122985 Peptide agonist Drugs 0.000 claims 21
- 150000001413 amino acids Chemical class 0.000 claims 12
- 102100038286 Vasoactive intestinal polypeptide receptor 2 Human genes 0.000 claims 11
- 210000004899 c-terminal region Anatomy 0.000 claims 10
- 101710137651 Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 claims 9
- 229940024606 amino acid Drugs 0.000 claims 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 6
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 5
- -1 3-phenylpropionyl group Chemical group 0.000 claims 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 3
- 238000011191 terminal modification Methods 0.000 claims 3
- 101000666868 Homo sapiens Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 239000000018 receptor agonist Substances 0.000 claims 2
- 229940044601 receptor agonist Drugs 0.000 claims 2
- OECHUGCITYQGCY-YUMQZZPRSA-N (2s)-5-amino-2-[[(2s)-2,5-diaminopentanoyl]amino]pentanoic acid Chemical compound NCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCN OECHUGCITYQGCY-YUMQZZPRSA-N 0.000 claims 1
- MFVFLUXOOXFBNS-GXQDVZPWSA-N 7-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-2-(4-aminobutyl)-3-oxoheptanoic acid;6-aminohexanoic acid Chemical compound NCCCCCC(O)=O.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)C(C(O)=O)CCCCN)SC[C@@H]21 MFVFLUXOOXFBNS-GXQDVZPWSA-N 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims 1
- 229930195721 D-histidine Natural products 0.000 claims 1
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine (R)-S-oxide group Chemical group N[C@@H](CCS(=O)C)C(=O)O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 108010050063 beta-naphthylsulfonyl-R-(d-Pip)-Ada-Abu-DYEPIPEEA-(Cha)-(d-Glu)-OH-AcOH Proteins 0.000 claims 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73029105P | 2005-10-26 | 2005-10-26 | |
| US74034205P | 2005-11-29 | 2005-11-29 | |
| US74336406P | 2006-02-28 | 2006-02-28 | |
| PCT/US2006/041550 WO2007050651A1 (en) | 2005-10-26 | 2006-10-24 | Selective vpac2 receptor peptide agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009519212A JP2009519212A (ja) | 2009-05-14 |
| JP2009519212A5 true JP2009519212A5 (enExample) | 2009-12-17 |
Family
ID=37716005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008537892A Pending JP2009519212A (ja) | 2005-10-26 | 2006-10-24 | 選択的ｖｐａｃ２受容体ペプチドアゴニスト |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7582608B2 (enExample) |
| EP (1) | EP1942941A1 (enExample) |
| JP (1) | JP2009519212A (enExample) |
| KR (1) | KR101057284B1 (enExample) |
| CN (1) | CN101296708B (enExample) |
| AU (1) | AU2006306236B2 (enExample) |
| BR (1) | BRPI0617740A2 (enExample) |
| CA (1) | CA2627716A1 (enExample) |
| EA (1) | EA012930B1 (enExample) |
| IL (1) | IL189922A0 (enExample) |
| NO (1) | NO20082345L (enExample) |
| WO (1) | WO2007050651A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10328316A1 (de) | 2003-06-23 | 2005-01-20 | Grünenthal GmbH | Verfahren zur Herstellung von Dimethyl-(3-aryl-buthyl)-aminverbindungen als pharmazeutische Wirkstoffe |
| CA2576755A1 (en) * | 2004-08-18 | 2006-03-02 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| US20090170775A1 (en) * | 2004-10-08 | 2009-07-02 | Transition Therapeutics, Inc. | Vasoactive intestinal polypeptide compositions |
| US7595294B2 (en) * | 2004-10-08 | 2009-09-29 | Transition Therapeutics, Inc. | Vasoactive intestinal polypeptide pharmaceuticals |
| DE102005052588A1 (de) * | 2005-11-02 | 2007-05-10 | Grünenthal GmbH | Verfahren zur Herstellung substituierter Dimethyl-(3-aryl-butyl)-amin-Verbindungen mittels homogener Katalyse |
| US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| TWI448447B (zh) | 2006-07-24 | 2014-08-11 | Gruenenthal Chemie | 製備（１ｒ，２ｒ）-３-（３-二甲胺基-１-乙基-２-甲基-丙基）-酚之方法 |
| JP2011526303A (ja) | 2008-06-27 | 2011-10-06 | デューク ユニバーシティ | エラスチン様ペプチドを含む治療剤 |
| MX366935B (es) * | 2009-08-14 | 2019-07-31 | Phasebio Pharmaceuticals Inc | Peptidos intestinales vasoactivos modificados. |
| CA2784748A1 (en) * | 2009-12-18 | 2011-06-23 | Idenix Pharmaceuticals, Inc. | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
| US9561262B2 (en) | 2011-06-06 | 2017-02-07 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
| EP3139949B1 (en) | 2014-05-08 | 2020-07-29 | Phasebio Pharmaceuticals, Inc. | Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis |
| WO2016130518A2 (en) | 2015-02-09 | 2016-08-18 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating muscle disease and disorders |
| CN115298194A (zh) * | 2020-03-30 | 2022-11-04 | 一丸自然美健有限公司 | Vipr2拮抗肽 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04193896A (ja) * | 1989-10-26 | 1992-07-13 | Meiji Seika Kaisha Ltd | 活性ペプチド |
| JPH0692991A (ja) * | 1991-02-28 | 1994-04-05 | Daicel Chem Ind Ltd | 新規活性ペプチド |
| WO1998002453A2 (en) | 1996-07-15 | 1998-01-22 | Universite Libre De Bruxelles | Peptidic ligands having a higher selectivity for the vip1 receptor than for the vip2 receptor |
| US6242563B1 (en) * | 1998-07-20 | 2001-06-05 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Peptide analogues |
| JP2002521390A (ja) | 1998-07-20 | 2002-07-16 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Ｐａｃａｐのペプチド類似体 |
| US20030087820A1 (en) * | 1999-01-14 | 2003-05-08 | Young Andrew A. | Novel exendin agonist formulations and methods of administration thereof |
| WO2000066629A1 (en) | 1999-04-30 | 2000-11-09 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| PE20010612A1 (es) | 1999-09-28 | 2001-07-12 | Bayer Corp | Agonistas del receptor 3 (r3) del peptido activador de la adenilato ciclasa de la pituitaria y su uso farmacologico |
| BR0306706A (pt) | 2002-01-08 | 2007-03-27 | Lilly Co Eli | peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêutica |
| RU2360922C2 (ru) * | 2002-07-12 | 2009-07-10 | БАЙЕР ХелсКер ЛЛСи | Агонисты рецептора (vpac2) гипофизарного пептида, активирующего аденилатциклазу (расар), и фармакологические способы их применения |
| BRPI0407936A (pt) * | 2003-03-19 | 2006-02-21 | Lilly Co Eli | composto de glp-1 peguilado, método de estimular o receptor de glp-1 em um indivìduo, e, uso de composto glp-1 peguilado |
| ATE461217T1 (de) * | 2003-12-18 | 2010-04-15 | Novo Nordisk As | Glp-1-verbindungen |
| KR20070009554A (ko) | 2004-01-27 | 2007-01-18 | 바이엘 파마슈티칼스 코포레이션 | 뇌하수체 아데닐레이트 사이클라제 활성화 펩티드(ｐａｃａｐ) 수용체 (ｖｐａｃ２) 작용제 및 이의약리학적 사용 방법 |
| EP1756156B1 (en) * | 2004-05-21 | 2008-10-22 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| CA2567635A1 (en) * | 2004-05-21 | 2005-12-01 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| CA2576755A1 (en) * | 2004-08-18 | 2006-03-02 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| JP2008515437A (ja) | 2004-10-08 | 2008-05-15 | フォーブス メディ−テック（リサーチ） インコーポレーテッド | 血管活性腸管ポリペプチド医薬品 |
| US7595294B2 (en) | 2004-10-08 | 2009-09-29 | Transition Therapeutics, Inc. | Vasoactive intestinal polypeptide pharmaceuticals |
| WO2008043102A2 (en) | 2006-10-06 | 2008-04-10 | Transition Therapeutics Inc. | Vasoactive intestinal polypeptide compositions |
-
2006
- 2006-10-24 BR BRPI0617740-9A patent/BRPI0617740A2/pt not_active IP Right Cessation
- 2006-10-24 KR KR1020087010055A patent/KR101057284B1/ko not_active Expired - Fee Related
- 2006-10-24 CN CN2006800398953A patent/CN101296708B/zh not_active Expired - Fee Related
- 2006-10-24 EA EA200801180A patent/EA012930B1/ru not_active IP Right Cessation
- 2006-10-24 JP JP2008537892A patent/JP2009519212A/ja active Pending
- 2006-10-24 WO PCT/US2006/041550 patent/WO2007050651A1/en not_active Ceased
- 2006-10-24 EP EP06817361A patent/EP1942941A1/en not_active Withdrawn
- 2006-10-24 US US12/090,656 patent/US7582608B2/en not_active Expired - Fee Related
- 2006-10-24 AU AU2006306236A patent/AU2006306236B2/en not_active Expired - Fee Related
- 2006-10-24 CA CA002627716A patent/CA2627716A1/en not_active Abandoned
-
2008
- 2008-03-04 IL IL189922A patent/IL189922A0/en unknown
- 2008-05-23 NO NO20082345A patent/NO20082345L/no not_active Application Discontinuation
-
2009
- 2009-07-24 US US12/508,584 patent/US7897573B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009519212A5 (enExample) | ||
| CN110229216B (zh) | 具有改善的药代动力学性质的坎普他汀类肽 | |
| DK2424557T3 (en) | MODIFIED COMPSTATIN WITH PEPTID BACKBONE AND C-TERMINAL MODIFICATIONS | |
| KR102812908B1 (ko) | 인크레틴 유사체의 제조 방법 | |
| EP2331567A1 (en) | Peptidomimetic macrocycles | |
| CN102171243A (zh) | N-端修饰的葡萄糖依赖性促胰岛素多肽(gip)类似物 | |
| CN115925790A (zh) | 用于合成α4β7肽拮抗剂的方法 | |
| JP2006525288A5 (enExample) | ||
| WO2017023933A2 (en) | Peptidomimetic macrocycles | |
| WO2006077035A9 (en) | Peptides with neuropeptide-2 receptor (y2r) agonist activity | |
| KR20110097807A (ko) | 뉴로펩티드-2-수용체(ｙ-2ｒ) 작용제 및 이의 용도 | |
| CN101437836B (zh) | 肽的硫酯化合物的制造方法 | |
| JP2005516996A5 (enExample) | ||
| AU2006306236B2 (en) | Selective VPAC2 receptor peptide agonists | |
| WO2019001459A1 (zh) | 一种肽类化合物、其应用及含其的组合物 | |
| CA2584805C (en) | Peptide anti-tumor agent | |
| WO2007021498A1 (en) | Selective vpac2 receptor peptide agonists | |
| CN114539358B (zh) | 一种多肽及制备方法与应用 | |
| JPWO2022096736A5 (enExample) | ||
| Mansfeld et al. | Synthesis and plasma stability of disulfide-bridged cyclic endomorphin-1 derivatives | |
| HU211694A9 (en) | Hexapeptides with sulphate ester groups | |
| Human | iolo ical e affilation of ne ar inine ao re in P analo e containin non nat ral a ino acid | |
| WO1992019644A1 (fr) | Peptide vasodilatateur | |
| WO1998043995A1 (en) | Novel anti-hiv complexes and medicinal compositions | |
| Klasová et al. | Effect of N-methylation of the peptide bond in the C-terminal part of the B-chain of human insulin on biological activity |